So, Why Are Clinicians Still Using Sulfonylureas? Given the continuing concerns about sulfonylureas and the new guidelines from the ACP, the Medscape poll results made me wonder why about one half of ...

Sulfonylureas are an older class of type 2 diabetes therapy but remain the most commonly prescribed antidiabetic drug after metformin. Patients taking metformin for type 2 diabetes (T2D) who switch to ...

The researchers found that over a mean follow-up of 1.1 years, sulfonylureas were associated with an increased risk of myocardial infarction, all-cause mortality, and severe hypoglycemia vs continuing ...

Metformin outperformed sulfonylureas in reducing CVD mortality. Compared with other drugs for type 2 diabetes, metformin is superior for reducing the risk of cardiovascular mortality. For patients ...

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "North America Sulfonylureas Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ResearchAndMarkets.com's ...

(HealthDay News) — For patients with type 2 diabetes mellitus (T2DM), sulfonylureas seem to increase levels of free fatty acids (FFA) and triglycerides (TG) and lower low-density lipoprotein ...

Sulfonylureas were flagged for excess cardiovascular risk when used for additional glucose lowering in type 2 diabetes (T2D) in an observational comparative effectiveness study. As second-line ...

DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly ...

Please provide your email address to receive an email when new articles are posted on . Use of sulfonylureas and insulin was associated with an increased risk for pancreatic cancer, whereas metformin ...

Sulfonylureas have been used to treat type 2 diabetes for many, many years. However, newer agents and a better understanding of type 2 diabetes have called their role into question. I recently posed ...

A comparative effectiveness research study compared MACE rates among initiators of sulfonylureas versus DPP4 inhibitors for T2D. Glipizide in particular showed a significant link to cardiovascular ...